New therapies in onco-hematology and new infectious risk factors

Reviews in Clinical and Experimental Hematology

Volumn 9, Issue 2, 2005, Pages

  Del Giudice, Ilaria ^a   Foà, Robin ^a,b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b Division of Hematology   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; FLUDARABINE; IMMUNOSUPPRESSIVE AGENT; RITUXIMAB;

CHRONIC LYMPHATIC LEUKEMIA; GRAFT VERSUS HOST REACTION; HEMATOLOGIC DISEASE; HUMAN; INFECTION RISK; LISTERIOSIS; LYMPHOCYTOPENIA; MUCOSAL DISEASE; NEUTROPENIA; PNEUMOCYSTOSIS; REVIEW; T LYMPHOCYTE; VIRUS INFECTION;

EID: 33744961220     PISSN: 1825151X     EISSN: 1825151X     Source Type: Journal    
DOI: None     Document Type: Review

References (86)

1. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med, 64: 328-340, 1966.
2. Young RC, Corder MP, Haynes HA, De Vita VT. Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am J Med, 52: 63-72, 1972.
3. Foa R, Fierro MT, Lusso P, et al. Reduced natural killer T-cells in B-cell chronic lymphocytic leukaemia identified by three monoclonal antibodies: Leu-11, A10, AB8.28. Br J Haematol, 62: 151-154, 1986.
4. Totterman TH, Carlsson M, Simonsson B, et al. T-cell activation and subset patterns are altered in B-CLL and correlate with the stage of the disease. Blood, 74: 786-792, 1989.
5. Bartik MM, Welker D, Kay NE. Impairments in immune cell function in B cell chronic lymphocytic leukemia. Semin Oncol, 25: 27-33, 1998.
6. Kyrtsonis MC, Mouzaki A, Maniatis A. Mechanisms of polyclonal hypogammaglobulinaemia in multiple myeloma (MM). Med Oncol, 16: 73-77, 1999.
7. Ravandi F, O'Brien S. Immune defects in patients with chronic lymphocytic leukemia. Cancer Immunol Immunother, 55: 197-209, 2006.
8. Jim R, Reinhard E. Agammaglobulinemia and chronic lymphocytic leukemia. Ann Intern Med, 44: 790-796, 1995.
9. Morrison VA. The infectious complications of chronic lymphocytic leukemia. Semin Oncol, 25: 98-106, 1998.
10. Mohty M, Jarrossay D, Lafage-Pochitaloff M, et al. Circulating blood dendritic cells from myeloid leukemia patients display quantitative and cytogenetic abnormalities as well as functional impairment. Blood, 98: 3750-3756, 2001.
11. Ratta M, Fagnoni F, Curti A, et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood, 100: 230-237, 2002.
12. Orsini E, Guarini A, Chiaretti S, et al. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Research, 63: 4497-4506, 2003.
13. Orsini E, Pasquale A, Maggio R, et al. Phenotypic and functional characterization of monocyte-derived dendritic cells in chronic lymphocytic leukaemia patients: influence of neoplastic CD19 cells in vivo and in vitro. Br J Haematol, 125: 720-728, 2004.
14. Orsini E, Guarini A, Foa R. Accessory cells, cytokine loops and cell-to-cell interactions in chronic lymphocytic leukemia. Rev Clin Exp Hematol, 4: 73-98, 2000.
15. Kraut EH. Clinical manifestations and infectious complications of hairy-cell leukaemia. Best Practice & Research Clinical Haematology, 16: 33-40, 2003.
16. Stewart DJ, Bodey GP. Infections in hairy cell leukemia (leukemic reticuloendotheliosis). Cancer, 47: 801-805, 1981.
17. Weinstein RA, Golomb HM, Grumet G, et al. Hairy cell leukemia: association with disseminated atypical mycobacterial infection. Cancer, 48: 380-383, 1981.
18. Bladè J, Rosinol L. Renal, hematologic and infectious complications in multiple myeloma. Best Practice & Research Clinical Haematology, 18: 635-652, 2005.
19. Fahey JL, Scoggins R, Utz JP, et al. Infection, antibody response and gamma globulin components in multiple myeloma and macroglobulinemia. Am J Med, 35: 698-707, 1963.
20. Lucas KG, Pollok KE, Emanuel DJ. Post-transplant EBV induced lymphoproliferative disorders. Leuk Lymphoma, 25: 1-8, 1997.
21. Kirk O, Pedersen C, Cozzi-Lepri A, et al. Non-Hodgkin lymphoma in HIV-infected patients in the era of highly active antiretroviral therapy. Blood, 98: 3406-3412, 2001.
22. Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol, 50: 292-296, 1993.
23. Fenchel K, Bergmann L, Wijermans P, et al. Clinical experience with fludarabine and its immunosuppressive effects in pretreated chronic lymphocytic leukemias and low-grade lymphomas. Leuk Lymphoma, 18: 485-492, 1995.
24. Abruzzo LV, Rosales CM, Medeiros LJ, et al. Epstein-Barr virus-positive B-cell lymphoproliferative disorders arising in immunodeficient patients previously treated with fludarabine for low-grade B-cell neoplasms. Am J Surg Pathol, 26: 630-636, 2002.
25. Girmenia C, Mauro FR, Rahimi S. Late listeriosis after fludarabine plus prednisone treatment. Br J Haematol, 87: 407-408, 1994.
26. Samonis G, Kontoyiannis DP. Infectious complications of purine analog therapy. Curr Opin Infect Dis, 14: 409-413, 2001.
27. Ravandi F, O'Brien S. Infections associated with purine analogs and monoclonal antibodies. Blood Reviews, 19: 253-273, 2005.
28. Anaissie EJ, Kontoyiannis DP, O'Brien S, et al. Infections in patients with chronic lymphocytic leukemia treated with fludarabine. Ann Intern Med, 129: 559-566, 1998.
29. Perkins JG, Flynn JM, Howard RS, Byrd JC. Frequency and type of serious infections in fludarabine-refractory B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma: implications for clinical trials in this patient population. Cancer, 94: 2033-2039, 2002.
30. Morrison VA, Rai KA, Peterson BL, et al. Impact of therapy with chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011. J Clin Oncol, 19: 3611-3621, 2001.
31. Pawson R, Dyer MJ, Barge R, et al. Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol, 15: 2667-2672, 1997.
32. Osterborg A, Dyer MJ, Bunjes D, et al. Phase II multicenter study of human CD52 antibody in previously treated chronic lymphocytic leukemia. European Study Group of CAMPATH-1H Treatment in Chronic Lymphocytic Leukemia. J Clin Oncol, 15: 1567-1574, 1997.
33. Lundin J, Osterborg A, Brittinger G, et al. CAMPATH-1H monoclonal antibody in therapy for previously treated low-grade non-Hodgkin's lymphomas: a phase II multicenter study. European Study Group of CAMPATH-1H Treatment in Low-Grade Non-Hodgkin's Lymphoma. J Clin Oncol, 16: 3257-3263, 1998.
34. Tang SC, Hewitt K, Reis MD, Berinstein NL. Immunosuppressive toxicity of CAMPATH1H monoclonal antibody in the treatment of patients with recurrent low grade lymphoma. Leuk Lymphoma, 24: 93-101, 1996.
35. Chakrabarti S, Mackinnon S, Chopra R, et al. High incidence of cytomegalovirus infection after nonmyeloablative stem cell transplantation: potential role of Campath-1H in delaying immune reconstitution. Blood, 99: 4357-4363, 2002.
36. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab. British J Haematology, 132: 3-12, 2005.
37. Rai KR, Freter CE, Mercier RJ, et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol, 20: 3891-3897, 2002.
38. Kennedy B, Rawstron A, Carter C, et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood, 99: 2245-2247, 2002.
39. Wierda W, O'Brien S, Wen S, et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol, 23: 4070-4078, 2005.
40. Keating MJ, O'Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol, 23: 4079-4088, 2005.
41. O'Brien SM, Kantarjian HM, Cortes J, et al. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia. J Clin Oncol, 19: 1414-1420, 2001.
42. Dervite I, Hober D, Morel P. Acute hepatitis B in a patient with antibodies to hepatitis B surface antigen who was receiving rituximab. N Engl J Med, 344: 68-69, 2001.
43. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis, 175: 1459-1466, 1997.
44. Denning DW, Marinus A, Cohen J, et al. An EORTC multicentre prospective survey of invasive aspergillosis in haematological patients: diagnosis and therapeutic outcome. EORTC Invasive Fungal Infections Cooperative Group. J Infect, 37: 173-180, 1998.
45. O'Brien S, Blijlevens N, Mahfouz T, Anaissie E. Infections in patients with hematological cancer: recent developments. Hematology, 438-472, 2003.
46. Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood, 100: 4358-4366, 2002.
47. van Kraaij MG, Verdonck LF, Rozenberg-Arska M, Dekker AW. Early infections in adults undergoing matched related and matched unrelated/mismatched donor stem cell transplantation: a comparison of incidence. Bone Marrow Transplant, 30: 303-309, 2002.
48. Van der Waaij D, Tielemans-Speltie TM, De Roeck-Houben AM. Infection by the distribution of biotypes of enterobacteriacease species in leukaemic patients treated under ward conditions and in units for protective isolation in seven hospitals in Europe. Infection, 5: 188-194, 1977.
49. Lecciones JA, Lee JW, Navarro EE, et al. Vascular catheter-associated fungemia in patients with cancer: analysis of 155 episodes. Clin Infect Dis, 14: 875-883, 1992.
50. Micozzi A, Cartoni C, Monaco M, et al. High incidence of infectious gastrointestinal complications observed in patients with acute myeloid leukemia receiving intensive chemotherapy for first induction of remission. Support Care Cancer, 4: 294-297, 1996.
51. Meyers JD, Flournoy N, Thomas ED. Risk factors for cytomegalovirus infection after human marrow transplantation. J Infect Dis, 153: 478-488, 1986.
52. Reusser P, Riddell SR, Meyers JD, Greenberg PD. Cytotoxic T-lymphocyte response to cytomegalovirus after human allogeneic bone marrow transplantation: pattern of recovery and correlation with cytomegalovirus infection and disease. Blood, 78: 1373-1380, 1991.
53. Wang FZ, Dahl H, Linde A, et al. Lymphotropic herpesviruses in allogeneic bone marrow transplantation. Blood, 88: 3615-3620, 1996.
54. Gratwohl A, Brand R, Frassoni F, et al. Cause of death after allogeneic haematopoietic stem cell transplantation (HSCT) in early leukaemias: an EBMT analysis of lethal infectious complications and changes over calendar time. Bone Marrow Transplant, 36: 757-769, 2005.
55. Slavin S, Nagler A, Naparstek E, et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood, 91: 756-763, 1998.
56. Sykes M, Preffer F, McAfee S, et al. Mixed lymphohaemopoietic chimerism and graft-versus-lymphoma effects after non-myeloablative therapy and HLA-mismatched bone-marrow transplantation. Lancet, 353: 1755-1759, 1999.
57. Khouri I, Giralt S, Champlin R. Non-myeloablative allogeneic hematopoietic transplantation and induction of graft-versus-malignancy. Cancer Treat Res, 110: 137-147, 2002.
58. Hermann S, Klein SA, Jacobi V, et al. Older patients with high-risk fungal infections can be successfully allografted using non-myeloablative conditioning in combination with intensified supportive care regimens. Br J Haematol, 113: 446-454, 2001.
59. Garban F, Attal M, Rossi JF, et al. Immunotherapy by non-myeloablative allogeneic stem cell transplantation in multiple myeloma: results of a pilot study as salvage therapy after autologous transplantation. Leukemia, 15: 642-646, 2001.
60. Kobbe G, Schneider P, Aivado M, et al. Reliable engraftment, low toxicity, and durable remissions following allogeneic blood stem cell transplantation with minimal conditioning. Exp Hematol, 30: 1346-1353, 2002.
61. Silberstein L, Davies A, Kelsey S, et al. Myositis, polyserositis with a large pericardial effusion and constrictive pericarditis as manifestations of chronic graft-versus-host disease after non-myeloablative peripheral stem cell transplantation and subsequent donor lymphocyte infusion. Bone Marrow Transplant, 27: 231-233, 2001.
62. Mattsson J, Uzunel M, Brune M, et al. Mixed chimaerism is common at the time of acute graft-versus-host disease and disease response in patients receiving non-myeloablative conditioning and allogeneic stem cell transplantation. Br J Haematol, 115: 935-944, 2001.
63. Schetelig J, Kroger N, Held TK, et al. Allogeneic transplantation after reduced conditioning in high risk patients is complicated by a high incidence of acute and chronic graft-versus-host disease. Haematologica, 87: 299-305, 2002.
64. Heslop HE, Savoldo B, Rooney CM. Cellular therapy of Epstein-Barr-virus- associated post-transplant lymphoproliferative disease. Best Pract Res Clin Haematol, 17: 401-413, 2004.
65. Locatelli F, Comoli P, Montagna D, et al. Innovative approaches of adoptive immune cell therapy in paediatric recipients of haematopoietic stem cell transplantation. Best Pract Res Clin Haematol, 17: 479-492, 2004.
66. Pagano JS, Blaser M, Buendia MA, et al. Infectious agents and cancer: criteria for a causal relation. Seminars in Cancer Biology, 14: 453-471, 2004.
67. Gentile M, Mauro FR, Guarini A, Foà R. New developments in the diagnosis, prognosis and treatment of chronic lymphocytic leukemia. Curr Opin Oncol, 17: 597-604, 2005.
68. Guarini A, Gaidano G, Mauro FR, et al. Chronic lymphocytic leukemia patients with highly stable and indolent disease show distinctive phenotypic and genotypic features. Blood, 102: 1035-1041, 2003.
69. Krober A, Seiler T, Benner A, et al. V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia. Blood, 100: 1410-1416, 2002.
70. Gentile M, Mauro FR, Calabrese E, et al. The prognostic value of CD38 expression in chronic lymphocytic leukaemia patients studied prospectively at diagnosis: a single institute experience. Br J Haematol, 130: 549-557, 2005.
71. Kay NE, Jelinek DF. B-CLL: is the enigma of disease heterogeneity about to be revealed? Blood, 100: 1110-1111, 2002.
72. Oscier DG, Gardiner AC, Mould SJ, et al. Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood, 100: 1177-1184, 2002.
73. Crespo M, Bosch F, Villamor N, et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med, 348: 1764-1775, 2003.
74. van Besien K, Keralavarma B, Devine S, Stock W. Allogeneic and autologous transplantation for chronic lymphocytic leukemia. Leukemia, 15: 1317-1325, 2001.
75. Tsiodras S, Samonis G, Keating MJ, Kontoyiannis DP. Infection and immunity in chronic lymphocytic leukemia. Mayo Clin Proc, 75: 1039-1054, 2000.
76. Morrison VA. Update on prophylaxis and therapy of infection in patients with chronic lymphocytic leukemia. Expert Rev Anticancer Ther, 1: 84-90, 2001.
77. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med, 346: 645-652, 2002.
78. Goldman JM. Treatment of chronic myeloid leukaemia: lessons and challenges. Int J Hematol, 76 (Suppl. 2): 189-192, 2002.
79. Seggewiss R, Lore K, Greiner E, et al. Imatinib inhibits T-cell receptor-mediated T-cell proliferation and activation in a dose-dependent manner. Blood, 105: 2473-2479, 2005.
80. Collins RH Jr, Shpilberg O, Drobyski WR, et al. Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation. J Clin Oncol, 15: 433-444, 1997.
81. Shimoni A, Gajewski JA, Donato M, et al. Long-Term follow-up of recipients of CD8-depleted donor lymphocyte infusions for the treatment of chronic myelogenous leukemia relapsing after allogeneic progenitor cell transplantation. Biol Blood Marrow Transplant, 7: 568-575, 2001.
82. Bjorkstrand B. European Group for Blood and Marrow Transplantation Registry studies in multiple myeloma. Semin Hematol, 38: 219-225, 2001.
83. Rajkumar SV, Gertz MA, Kyle RA, Greipp PR. Current therapy for multiple myeloma. Mayo Clin Proc, 77: 813-822, 2002.
84. Badros A, Barlogie B, Morris C, et al. High response rate in refractory and poor-risk multiple myeloma after allotransplantation using a nonmyeloablative conditioning regimen and donor lymphocyte infusions. Blood, 97: 2574-2579, 2001.
85. Alyea E, Weller E, Schlossman R, et al. T-cell - depleted allogeneic bone marrow transplantation followed by donor lymphocyte infusion in patients with multiple myeloma: induction of graft-versus-myeloma effect. Blood, 98: 934-939, 2001.
86. Kroger N, Schwerdtfeger R, Kiehl M, et al. Autologous stem cell transplantation followed by a dose-reduced allograft induces high complete remission rate in multiple myeloma. Blood, 100: 755-760, 2002.